Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Plasma Eyedrops for Severe Dry Eye
NCT03768115Phase 1Withdrawn
- Sponsor
- Singapore National Eye Centre
- Start
- Nov 2018
- Primary completion
- Oct 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous plasma exosome eye drops in dry eye syndrome (DED), sponsored by Singapore National Eye Centre. Primary endpoint: Change from baseline dry eye symptoms at 1 year. Planned start Nov 2018; status: withdrawn.
02
Drugs
autologous plasma exosome eye drops
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT03768115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768115.